TY  - JOUR
AU  - Brandi, Paola
AU  - Conejero, Laura
AU  - Cueto, Francisco J
AU  - Martínez-Cano, Sarai
AU  - Dunphy, Gillian
AU  - Gómez, Manuel J
AU  - Relaño, Carlos
AU  - Saz-Leal, Paula
AU  - Enamorado, Michel
AU  - Quintas, Ana
AU  - Dopazo, Ana
AU  - Amores-Iniesta, Joaquin
AU  - Del Fresno, Carlos
AU  - Nistal-Villán, Estanislao
AU  - Ardavín, Carlos
AU  - Nieto, Antonio
AU  - Casanovas, Miguel
AU  - Subiza, José Luis
AU  - Sancho, David
PY  - 2022
DO  - 10.1016/j.celrep.2021.110184
UR  - http://hdl.handle.net/20.500.12105/15092
AB  - MV130 is an inactivated polybacterial mucosal vaccine that confers protection to patients against recurrent respiratory infections, including those of viral etiology. However, its mechanism of action remains poorly understood. Here, we find that...
LA  - eng
PB  - Cell Press
KW  - Administration, Intranasal
KW  - Animals
KW  - Antibodies, Viral
KW  - Bacteria
KW  - Bacterial Vaccines
KW  - Candidiasis
KW  - Cell Line
KW  - Chlorocebus aethiops
KW  - Cytokines
KW  - Humans
KW  - Immunity, Mucosal
KW  - Influenza A virus
KW  - L Cells
KW  - Lung
KW  - Metformin
KW  - Mice
KW  - Mice, Inbred C57BL
KW  - Mice, Knockout
KW  - Monocytes
KW  - Orthomyxoviridae Infections
KW  - Respiratory Mucosa
KW  - Respiratory Tract Infections
KW  - Vaccines, Inactivated
TI  - Trained immunity induction by the inactivated mucosal vaccine MV130 protects against experimental viral respiratory infections.
TY  - journal article
ER  -